William T. Lowther, Ph.D.Wake Forest School of Medicine

William T. Lowther, Ph.D.

Associate Professor,

Contact Information

Academic: 336-716-7230 | Department: 336-716-7230


Education & Training

  • B.S., Stetson University, 1989
  • Ph.D., University of Florida, 1994
  • Fellowship, Molecular Biology, University of Florida College, 2002


  • Am Chemical Society
  • American Crystallographic Asso
  • Am Soc Of Biochem & Mol Biolog
William T. Lowther, Ph.D.

William T. Lowther, Ph.D.

Associate Professor, Biochemistry

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm, metabolism, model development, rare diseases, structural biology, vascular diseases

Contact Information

Academic: 336-716-7230 | Department: 336-716-7230


Recent Publications

Li X, Knight J, Fargue S, Buchalski B, Guan Z, Inscho EW, Liebow A, Fitzgerald K, Querbes W, Todd Lowther W, Holmes RP. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Biochim Biophys Acta. 2016;1862(2):233-239.

Ritchie MK, Johnson LC, Clodfelter JE, Pemble CW IV, Fulp BE, Furdui CM, Kridel SJ, Lowther WT. Crystal structure and substrate specificity of human thioesterase 2: insights into the molecular basis for the modulation of fatty acid synthase. J Biol Chem. 2016;291(7):3520-3530.

Hill TK, Davis AL, Wheeler FB, Kelkar SS, Freund EC, Lowther WT, Kridel SJ, Mohs AM. Development of a self-assembled nanoparticle formulation of Orlistat, Nano-ORL, with increased cytotoxicity against human tumor cell lines. Mol Pharm. 2016;13(3):720-728.

Poynton RA, Peskin AV, Haynes AC, Lowther WT, Hampton MB, Winterbourn CC. Kinetic analysis of structural influences on the susceptibility of peroxiredoxins 2 and 3 to hyperoxidation. Biochem J. 2016;473(4):411-421.

Summitt CB, Johnson LC, Jonsson TJ, Parsonage D, Holmes RP, Lowther WT. Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria. Biochem J. 2015;466(2):273-281.

Cunniff B, Newick K, Nelson KJ, Wozniak AN, Beuschel S, Leavitt B, Bhave A, Butnor K, Koenig A, Chouchani ET, James AM, Haynes AC, Lowther WT, Murphy MP, Shukla A, Heintz NH. Disabling mitochondrial peroxide metabolism via combinatorial targeting of peroxiredoxin 3 as an effective therapeutic approach for malignant mesothelioma. PLoS One. 2015;10(5):e0127310.

Li X, Knight J, Todd Lowther W, Holmes RP. Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3. Biochim Biophys Acta. 2015;1852(12):2700-2705.

Bolduc J, Reisz-Haines J, Nelson K, Furdui C, Lowther WT. Determining the molecular basis for differential hyperoxidation sensitivity in peroxiredoxin 1 & 2 [abstract]. FASEB J. 2015;29(Suppl 1):895.10.

Chen H, Gu Z, Zhang H, Wang M, Chen W, Lowther WT, Chen YQ. Expression and purification of integral membrane fatty acid desaturases. PLoS One. 2013;8(3):e58139.

Haynes AC, Qian J, Reisz JA, Furdui CM, Lowther WT. Molecular basis for the resistance of human mitochondrial 2-Cys peroxiredoxin 3 to hyperoxidation. J Biol Chem. 2013;288(41):29714-23.

Jiang J, Johnson LC, Knight J, Callahan MF, Riedel TJ, Holmes RP, Lowther WT. Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria. Am J Physiol Gastrointest Liver Physiol. 2012;302(6):G637-G643.

Lema Tome CM, Palma E, Ferlaga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem. 2012;287(17):14012-22.

Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012;1822(10):1544-1552.

Lowther WT, Haynes AC. Reduction of cysteine sulfinic acid in eukaryotic, typical 2-Cys peroxiredoxins by sulfiredoxin. Antioxid Redox Signal. 2011;15(1):99-109.

Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT. Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. PLoS ONE. 2011;6(10):e26021.

Klomsiri C, Nelson KJ, Bechtold E, Soito L, Johnson LC, Lowther WT, Ryu S-E, King SB, Furdui CM, Poole LB. Use of dimedone-based chemical probes for sulfenic acid detection evaluation of conditions affecting probe incorporation into redox-sensitive proteins. Methods Enzymol. 2010;473():77-94.

Cox AG, Pearson AG, Pullar JM, Jonsson TJ, Lowther WT, Winterbourn CC, Hampton MB. Mitochondrial peroxiredoxin 3 is more resilient to hyperoxidation than cytoplasmic peroxiredoxins. Biochem J. 2009;421(1):51-58.

Jonsson TJ, Johnson LC, Lowther WT. Protein engineering of the quaternary sulfiredoxin.peroxiredoxin enzyme.substrate complex reveals the molecular basis for cysteine sulfinic acid phosphorylation. J Biol Chem. 2009;284(48):33305-10.

Jonsson TJ, Johnson LC, Lowther WT. Structure of the sulphiredoxin-peroxiredoxin complex reveals an essential repair embrace. Nature. 2008;451(7174):98-101.

Murray MS, Holmes RP, Lowther WT. Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design. Biochemistry. 2008;47(8):2439-2449.

Jonsson TJ, Tsang AW, Lowther WT, Furdui CM. Identification of intact protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin by human sulfiredoxin. J Biol Chem. 2008;283(34):22890-94.

Jonsson TJ, Murray MS, Johnson LC, Lowther WT. Reduction of cysteine sulfinic acid in peroxiredoxin by sulfiredoxin proceeds directly through a sulfinic phosphoryl ester intermediate. J Biol Chem. 2008;283(35):23846-51.

Brunell DJ, Lowther T, Sagher D, Brot N, Weissbach H. A disulfide intermediate is required for the reduction of methionine sulfoxide reductase by thioredoxin [abstract]. FASEB J. 2007;21(5):A275.

Lin Z, Johnson LC, Weissbach H, Brot N, Lively MO, Lowther WT. Free methionine-(R)-sulfoxide reductase from Escherichia coli reveals a new GAF domain function. Proc Natl Acad Sci U S A. 2007;104(23):9597-9602.

Pemble CW IV, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007;14(8):704-709.

Kridel SJ, Lowther WT, Pemble CW IV. Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Investig Drugs. 2007;16(11):1817-1829.

Jonsson TJ, Lowther WT. The peroxiredoxin repair proteins. Subcell Biochem. 2007;44():115-141.

Jonsson TJ, Johnson LC, Lowther WT. Structure of the sulfiredoxin-peroxiredoxin complex reveals basis for cysteine sulfinic acid repair [abstract]. Free Radic Biol Med. 2007;43(Suppl 1):S110.

Brot N, Collet J-F, Johnson LC, Jonsson TJ, Weissbach H, Lowther WT. The thioredoxin domain of Neisseria gonorrhoeae PilB can use electrons from DsbD to reduce downstream methionine sulfoxide reductases. J Biol Chem. 2006;281(43):32668-75.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Biochemistry

William T. Lowther, Ph.D.

William T. Lowther, Ph.D.

Associate Professor, Biochemistry

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.